Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896555 | 1.00 | AKR1C4 (0.45) | AKR1C4AKR1C3AKR1C2PTGS1 | |
| SCHEMBL2477637 | 0.84 | AKR1C4 (0.33) | AKR1C4AKR1C3AKR1C2PTGS1 | |
| SCHEMBL2478484 | 0.84 | AKR1C4 (0.33) | AKR1C4AKR1C3AKR1C2PTGS1 | |
| SCHEMBL10385820 | 0.77 | AKR1C4 (0.40) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL28625241 | 0.77 | TLR4 (0.33) | — | |
| SCHEMBL234408 | 0.75 | PRKCA (0.37) | — | |
| SCHEMBL2240463 | 0.75 | PRKCA (0.37) | — | |
| SCHEMBL28619636 | 0.74 | PRKCA (0.39) | — | |
| SCHEMBL11804557 | 0.73 | AKR1C4 (0.38) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL57727 | 0.73 | AKR1C4 (0.38) | AKR1C4AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150240220-A1 | NOVEL UDP-GLYCOSYLTRANSFERASE DERIVED FROM GINSENG AND USE THEREOF | INTELLIGENT SYNTHETIC BIOLOGY CENTER (KR) | 2015-08-27 | — | — | US | disclosed |
| EP-2503885-A2 | PLANT GROWTH REGULATION | Syngenta Participations AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063946-A2 | PLANT GROWTH REGULATION | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240220-A1 | NOVEL UDP-GLYCOSYLTRANSFERASE DERIVED FROM GINSENG AND USE THEREOF | UGGT1, FNTA, UGDH | AKR1C4 2193/4885AKR1C3 2373/4885AKR1C2 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.